Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 30Hodgkin Disease 17Leukemia, Lymphocytic, Chronic, B-Cell 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Myelodysplastic Syndromes 14Lymphoma, Non-Hodgkin 13Leukemia, Myeloid, Acute 13Myeloproliferative Disorders 11Lymphoma, Mantle-Cell 11Primary Myelofibrosis 10Neoplasms, Plasma Cell 10Lymphoma, Large B-Cell, Diffuse 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Waldenstrom Macroglobulinemia 9Lymphoma, Follicular 9Lymphoma 9Leukemia 9Graft vs Host Disease 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myelomonocytic, Chronic 8Burkitt Lymphoma 8Myelodysplastic-Myeloproliferative Diseases 7Leukemia, Prolymphocytic 7Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 7Leukemia, Myeloid, Accelerated Phase 7Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large-Cell, Anaplastic 6Leukemia, Myeloid, Chronic-Phase 6Blast Crisis 6Lymphoma, T-Cell, Cutaneous 5

Interventions

Melphalan 2Filgrastim 2Fibroblast Growth Factor 7 2Cyclophosphamide 2Amifostine 2sargramostim 1Sirolimus 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Ifosfamide 1Etoposide 1Epoetin Alfa 1Deoxycytidine 1Cytarabine 1Carboplatin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Sirolimus × Plasma cell × Clear all
NCT00317798 2011-08-30

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

University of Rochester

Phase 1 Completed
18 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡